

Supplemental Digital Content. The Supplemental Digital Content was not copyedited by *Archives of Pathology & Laboratory Medicine*.

Supplementary Table 1. Non-oro-pharyngeal squamous cell carcinoma cases (oral cavity, nasal cavity/nasopharynx, hypopharynx, and larynx) in each time period, classified according to how the high-risk human papillomavirus evaluation deviated from the published CAP guideline.

Non-Oropharyngeal SCC	Before College of American Pathologists Guideline¹ (1/1/17 to 12/17/17)	After College of American Pathologists Guideline¹ (12/18/17 to 5/1/19)	After Online Publication, Before Print Publication (12/18/17 to 4/30/18)	After Print Publication (5/1/18 to 7/31/18)	After Print Publication (8/1/18 to 12/31/18)	After Print Publication (1/1/19 to 5/1/19)
<i>Oral Cavity SCC</i>						
Cases not ordered correctly	19/42 (45.2%)	43/93 (46.2%)	15/24 (62.5%)	8/19 (42.1%)	13/31 (41.9%)	7/19 (36.8%)
p16 IHC ordered	18/19 (94.7%)	41/43 (95.3%)	15/15 (100.0%)	8/8 (100.0%)	12/13 (92.3%)	6/7 (85.7%)
HPV ^a ordered	1/19 (5.3%)	0/43 (0.0%)	0/15 (0.0%)	0/8 (0.0%)	0/13 (0.0%)	0/7 (0.0%)
p16 IHC and HPV ^a ordered	0/19 (0.0%)	2/43 (4.7%)	0/15 (0.0%)	0/8 (0.0%)	1/13 (7.7%)	1/7 (14.3%)
<i>Nasal Cavity/Nasopharyngeal SCC</i>						
Cases not ordered correctly	0/0 (0.0%)	5/13 (38.5%)	1/5 (20.0%)	0/2 (0.0%)	1/1 (100.0%)	3/5 (60.0%)
p16 IHC ordered	0/0 (0.0%)	5/5 (100.0%)	1/1 (100.0%)	0/0 (0.0%)	1/1 (100.0%)	3/3 (100.0%)
<i>Hypopharyngeal SCC</i>						
Cases not ordered correctly	2/3 (66.7%)	7/13 (53.8%)	6/8 (75.0%)	0/2 (0.0%)	1/3 (33.3%)	0/0 (0.0%)
p16 IHC ordered	2/2 (100.0%)	6/7 (85.7%)	5/6 (83.3%)	0/0 (0.0%)	1/1 (100.0%)	0/0 (0.0%)
p16 IHC and HPV ^a ordered	0/2 (0.0%)	1/7 (14.3%)	1/6 (16.7%)	0/0 (0.0%)	0/1 (0.0%)	0/0 (0.0%)
<i>Laryngeal SCC</i>						
Cases not ordered correctly	9/23 (39.1%)	14/44 (31.8%)	8/16 (50.0%)	1/5 (20.0%)	3/16 (18.8%)	2/7 (28.6%)
p16 IHC ordered	9/9 (100.0%)	12/14 (85.7%)	7/8 (87.5%)	0/1 (0.0%)	3/3 (100.0%)	2/2 (100.0%)
HPV ^a ordered	0/9 (0.0%)	2/14 (14.3%)	1/8 (12.5%)	1/1 (100.0%)	0/3 (0.0%)	0/2 (0.0%)

¹ Lewis JS, Jr., Beadle B, Bishop JA, et al. Human Papillomavirus Testing in Head and Neck Carcinomas: Guideline From the College of American Pathologists. *Arch Pathol Lab Med*. 2018;142(5):559-597.

^a Refers to use of either HPV RNA or DNA ISH or HPV DNA PCR.

IHC, Immunohistochemistry; HPV, Human papillomavirus; ISH, in situ hybridization; PCR, polymerase chain reaction; SCC, Squamous cell carcinoma